The number of people living with chronic conditions is growing as a result of lifestyle, increased life-expectancy, improved treatment options and growing diagnostic activity [ 1].
The number of patients with chronic disease is growing as a result of inappropriate lifestyle, growing diagnostic activity, improved treatment options and increased life-expectancy [ 2].
Since the early 1990s, functional imaging with positron emission tomography (PET) has been the fastest growing diagnostic modality in oncology [ 1, 2].
This is becoming increasingly important considering the effects of the rapid technical advances, the growing diagnostic possibilities, and the more widespread use of ultrasound.
The discrimination between early erythroid cells and myeloid precursor cells as well as their exact characterization are of clinical significance, especially in such pathological conditions as myelodysplastic syndromes, in which FCM analyses are of growing diagnostic and prognostic relevance.
Next-generation sequencing technologies, particularly RNA sequencing (RNA-seq), have revealed an increasing number of recurrent fusions in a variety of cancers, and it is likely that their detection will have growing diagnostic and prognostic utility.
To monitor and quantify their occurrence during the growing season, diagnostic system based on real-time PCR was developed.
Formal cost-benefit analyses of these options are limited [ 39– 42], and further studies are needed in this growing molecular diagnostic area.
As these may be negative on positron emission tomography and slow growing, the diagnostic algorithms that are used for solid nodules have to be modified for non-solid nodules.
